AI assistant
EXELIXIS, INC. — Director's Dealing 2019
Oct 4, 2019
30561_dirs_2019-10-03_e0ece777-9039-4168-8825-306df609b17d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2019-10-01
Reporting Person: Schwab Gisela (Pres, Prod Dev & Med Aff & CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-10-01 | Common Stock | M | 30000 | $5.51 | Acquired | 354331 | Direct |
| 2019-10-01 | Common Stock | S | 30000 | $17.87 | Disposed | 324331 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-10-01 | Option (right to buy) | $5.51 | M | 30000 | Disposed | 2020-09-17 | Common Stock (30000.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 14880 | Indirect |
Footnotes
F1: Includes 71,448 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.63 to $18.02. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of October 1, 2019.
F5: The option, representing the right to purchase a total of 160,000 shares of Exelixis, Inc. common stock, became exercisable as to 50% of such stock option on July 20, 2015 upon the satisfaction of one of the two performance goals set by the Compensation Committee. On December 10, 2014, the Compensation Committee determined that the second performance goal for the option had not, and would not, be achieved, resulting in the Reporting Person forfeiting the remaining 50% of such stock option.